Monte Rosa Therapeutics stock
GLUENASDAQMonte Rosa Therapeutics, Inc., HealthcareISIN US61225M1027
34Score 34 out of 100, Weak
Price and trend
37 / 100
Price history
−28% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 39% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 37).
The price is 59% below its 52-week high. Largest decline in 5 years: 94% (September 2021 to October 2023).
Chart figures for advanced users
- SMA 50$11.50
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$16.86
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)37
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.74
- The lowest closing price of the last twelve months.
- Resistance$25.31
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Monte Rosa Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.05B, is number 190 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $123.67M (up 63.5% year on year) and a loss of $38.63M.
- For fiscal 2026, analysts expect on average revenue of $72.85M (down 41.1%) and adjusted earnings per share of −$1.42.
Show more
- MEQIRI Score 34 out of 100 (Weak): rank 647 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $577.73M, financial debt $36.27M.Stability 68
Weaknesses
- DilutionShare count up 49% since 2020.Capital allocation 18
- Loss-makingLoss of $130.97M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$174.39M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue rose 326% on the same quarter a year earlier. Revenue turned from negative at the start of the period to positive ($123.67M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 93%, operating −44%, net −31%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 16 Mar 2027in 124 days
- Last reported
- 5 Nov 2026EPS reported $0.03 (expected −$0.21)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.42+2.9%
- Revenue
- $72.85M+6.1%
- Earnings per share
- −$1.86+0.1%
- Revenue
- $64.61M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $2.54M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Bowen MatthewSale
5 Oct 2026, Principal Accounting Officer
- Shares
- 13
- Price
- $10.56
- Value
- $137
- Warmuth MarkusSale
16 Jul 2026, President & CEO
- Shares
- 9,500
- Price
- $23.18
- Value
- $220,219
- Champoux JenniferSale
15 Jul 2026, Chief Operating Officer
- Shares
- 4,351
- Price
- $23.38
- Value
- $101,730
Show 15 more
- Townson SharonSale
6 Jul 2026, Chief Scientific Officer
- Shares
- 6,000
- Price
- $23.31
- Value
- $139,849
- Janku FilipSale
30 Jun 2026, Chief Medical Officer
- Shares
- 5,407
- Price
- $24.50
- Value
- $132,472
- Janku FilipSale
29 Jun 2026, Chief Medical Officer
- Shares
- 6,000
- Price
- $22.95
- Value
- $137,700
- Manning Anthony M.Sale
29 Jun 2026, Board
- Shares
- 10,000
- Price
- $23.11
- Value
- $231,100
- Janku FilipSale
24 Jun 2026, Chief Medical Officer
- Shares
- 30,000
- Price
- $21.42
- Value
- $642,681
- Janku FilipSale
23 Jun 2026, Chief Medical Officer
- Shares
- 11,845
- Price
- $20.22
- Value
- $239,522
- Champoux JenniferSale
23 Jun 2026, Chief Operating Officer
- Shares
- 2,175
- Price
- $20.00
- Value
- $43,500
- Townson SharonSale
23 Jun 2026, Chief Scientific Officer
- Shares
- 3,000
- Price
- $20.00
- Value
- $60,000
- Champoux JenniferSale
17 Jun 2026, Chief Operating Officer
- Shares
- 2,176
- Price
- $19.00
- Value
- $41,344
- Townson SharonSale
17 Jun 2026, Chief Scientific Officer
- Shares
- 3,000
- Price
- $19.00
- Value
- $57,000
- Warmuth MarkusSale
1 Jun 2026, President & CEO
- Shares
- 5,466
- Price
- $19.44
- Value
- $106,253
- Townson SharonSale
29 May 2026, Chief Scientific Officer
- Shares
- 6,000
- Price
- $19.87
- Value
- $119,220
- Champoux JenniferSale
27 May 2026, Chief Operating Officer
- Shares
- 2,175
- Price
- $20.00
- Value
- $43,500
- Champoux JenniferSale
22 May 2026, Chief Operating Officer
- Shares
- 2,176
- Price
- $19.00
- Value
- $41,344
- Manning Anthony M.Sale
21 May 2026, Board
- Shares
- 10,000
- Price
- $18.01
- Value
- $180,100
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Monte Rosa Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 34
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- InventivaIVA.PA $1.07B31
- Corvus PharmaceuticalsCRVS $1.06B38
- Basilea PharmaceuticaBSLN.SW $1.06B74
- Jade BiosciencesJBIO $1.05B42
- Odyssey TherapeuticsODTX $1.01B44
- ImmaticsIMTX $1B29
- Climb BioCLYM $980.38M45
- PhilogenPHIL.MI $934.29M68
ETFs that hold Monte Rosa Therapeutics
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.06% | 0.35% | €1.21B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.03% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 21 Nov 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.